SOURCE: Bilcare Global Clinical Supplies

April 30, 2008 06:00 ET

Bilcare Global Clinical Supplies Forms Corporate Advisory Board; Inducts Former Pfizer President and the Executive Director of Waterloo Institute of Nanotechnology as Members

PHOENIXVILLE, PA--(Marketwire - April 30, 2008) - Bilcare Global Clinical Supplies, a leading single-source provider of clinical trial services, has formed its first corporate Advisory Board. Bilcare Limited's Chairman and Managing Director Mohan Bhandari announced former Pfizer President John LaMattina, Ph.D., and Waterloo Institute of Nanotechnology Executive Director Arthur Carty, Ph.D., D.Sc., as the board's inaugural members. Dr. LaMattina will serve as its Chairman. The advisory board was created to provide the Bilcare GCS Senior Management Team with independent scientific industry expertise and insight to assist in the accomplishment of scientific and business objectives in support of the company's global mission. "The formation of our corporate Advisory Board is another major milestone in our mission to make Bilcare GCS the global leader in the clinical trial supplies arena," said Bhandari. "The addition of these accomplished members will prove to be a tremendous asset to research and innovation initiatives of our company."

Dr. LaMattina had a distinguished 30-year career at Pfizer where he held various positions, including Senior Vice President of Pfizer Inc., and President of Pfizer Global Research and Development. In this role, Dr. LaMattina oversaw the drug discovery and development efforts of more than 12,000 colleagues in the United States, Europe and Asia. Dr. LaMattina is the author of 23 scientific publications and holds 15 U.S. patents. He is the 2004 recipient of the American Diabetes Association Award for Leadership and Commitment in the Fight Against Diabetes. Dr. LaMattina serves on the Board of Trustees of Boston College. "I am honored to be on the corporate Advisory Board of a company that is on the rise and gaining well-deserved recognition throughout the industry," said LaMattina. "I am confident that the Advisory Board will play a pivotal role in the future success of Bilcare's contribution to the clinical research industry."

Dr. Carty is the first Executive Director of the Waterloo Institute of Nanotechnology and the former National Science Advisor to Canada's Prime Minister. A noted academic, Dr. Carty had a distinguished career as the President of the National Research Council of Canada from 1994 to 2004 after which he was appointed as the National Science Advisor. Prior to his recent return to the institute, Dr. Carty spent 27 years as a professor of chemistry at the University of Waterloo, serving as Chairman of the chemistry department and Dean of Research. He has authored more than 285 papers in refered journals and multiple book chapters and review articles, and also has five patents. Dr. Carty is a distinguished member of multiple boards including two for the Networks of Centres of Excellence and Genome Canada. Dr. Carty is both an Officer of the Order of Canada and Officer de L'Ordre National du Merite of France. "Serving on the corporate Advisory Board is an honor and comes with great responsibility," said Carty. "I am committed to providing technology and biotech expertise I can to Bilcare GCS to further its business objectives."

"I am certain that both of our Board members with their extensive knowledge, experience, and business networks will provide immense benefits to our company," said Bilcare GCS CEO Vito Mangiardi. "We are honored to have Dr. LaMattina and Dr. Carty as an integral part of the Bilcare team and look forward to a long association with them and to their successful contribution especially in the areas of technology, research and innovation."

Bilcare Global Clinical Supplies serves the Americas, Europe, and Asia with clinical trial materials support, services and complete project management. Our services for solid, semi-solid, liquid, DEA (CI-V) and biotech clinical trial materials (CTM) satisfy a broad range of requirements, from pre-formulation research and development, analytical services and clinical supplies packaging and labeling, to IVRS, controlled temperature (cold and frozen chain) CTM storage, distribution worldwide, and returns and destructions accountability.

For more information about Bilcare Global Clinical Supplies, please visit our website at www.BilcareGCS.com.

Contact Information

  • Media Contacts:
    Deborah Buscarino
    Director of Marketing
    Phone: 610-422-3204
    Fax: 610-935-4321
    E-mail: Email Contact

    Vito Mangiardi
    Chief Executive Officer
    Bilcare Global Clinical Supplies
    Phone: 610-551-2035
    Fax: 610-935-4321
    E-mail: Email Contact